Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Cabergoline and LGD-4033 Interaction: Synergistic | Peptide Database

Compound Profiles Cabergoline Dopamine Agonist | Prolactin Management Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypot

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Cabergoline

Dopamine Agonist | Prolactin Management

Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypothalamic dopamine acting on these D2 receptors, and cabergoline mimics this inhibitory signal with high affinity and prolonged duration.

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Combined Organ Load

Frequently Asked Questions

Can I take Cabergoline with LGD-4033?

Yes, Cabergoline and LGD-4033 can generally be taken together. LGD-4033 supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.

Is Cabergoline and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.

What are the interactions between Cabergoline and LGD-4033?

LGD-4033 supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. This assessment has 55% confidence and is inferred from pharmacological mechanism analysis.

How should I time Cabergoline and LGD-4033?

Cabergoline has a half-life of ~63-69 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Bronchogen — share findings, ask questions, and learn from real experiences Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair. Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.

Source: peptide-db.com ↗

Community Research

Join others researching Vilon — share findings, ask questions, and learn from real experiences Vilon is a Khavinson bioregulator dipeptide (KE) consisting of lysine and glutamic acid, originally isolated from thymus gland extracts. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it acts as a molecular signaling compound that restores normal gene expression and protein synthesis in immune and epithelial cells. Research shows Vilon increases mean lifespan by 20-40% in animal studies and suppresses tumor development. Vilon works through epigenetic modulation, restoring chromatin structure and gene expression in immune cells. It stimulates thymocyte proliferation, activates T-helper cells, and increases the proliferative index in thymus tissue (from 26% to 37% in studies). The peptide modulates tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and helps rejuvenate aged immune systems by restoring proper gene expression patterns.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

VIP has a very short half-life of approximately 2 minutes in blood, requiring careful dosing strategies. Subcutaneous or intravenous administration. Rapid degradation limits bioavailability; analogs like stearyl-Nle17-VIP (SNV) are 100-fold more potent. General use 50-100 mcg 1-2x daily SubQ or IV Research protocols 100-200 mcg As directed

Source: peptide-db.com ↗
Side effects

Common Side Effects

Injection site reactions Mild fatigue during adaptation Potential hypoglycemia

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides